Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

Data Build on Breakthrough Therapy Designation of the Combination of Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer


Clinically Meaningful Response Rates and Manageable Safety and... | May 25, 2023

Related Keywords

London ,City Of ,United Kingdom ,Berlin ,Germany ,United States ,American ,Racheln Grisham ,Susana Banerjee ,European Network Of Gynaecological Oncological Trial ,Exchange Commission ,Company Annual Report On Form ,National Cancer Institute ,Gynecologic Oncology Group ,European Society Of Gynaecological Oncology ,Foundation Inc ,Partners Program ,Amgen ,European Network For Gynaecological Oncological Trial ,Chugai Pharmaceutical Co Ltd ,Drug Administration ,Secura Bio Inc ,Raf And Mek Program ,Institute Of Cancer Research ,American Society Of Clinical Oncology Annual Meeting ,Team Leader In Women Cancers ,Verastem Oncology ,American Society ,Clinical Oncology Annual Meeting ,Breakthrough Therapy Designation ,Selection Phase ,Expansion Phase ,Consultant Medical Oncologist ,Royal Marsden ,Team Leader ,Cancer Research ,Defactinib Combination ,Section Head ,Ovarian Cancer ,Westchester Gynecologic Medical Oncology ,Memorial Sloan Kettering Cancer Center ,Breakthrough Therapy ,Low Grade Serous Ovarian Cancer ,European Network ,Gynaecological Oncological Trial ,European Society ,Gynaecological Oncology ,Secura Bio ,Annual Report ,Verastem ,Nc Stock Exchange ,News ,Information ,Press Release ,Data ,Build ,N ,Breakthrough ,Therapy ,Resignation ,F ,The ,Combination ,Avutometinib ,End ,Defactinib ,Serous ,Ovarian ,Meaningful ,Response ,Rates ,Unmanageable ,Afety Vstm Us92337c1045 ,